Skip to main content
. Author manuscript; available in PMC: 2017 Dec 15.
Published in final edited form as: Clin Cancer Res. 2016 Jun 15;22(24):6176–6191. doi: 10.1158/1078-0432.CCR-15-3107

Figure 2.

Figure 2

BMI-1 inhibition reduces TIC number and interferes with self-renewal capacity in vitro. A, Fold adhesion of rapidly adherent CD49bhiCD29hiCD44hi cells evaluated upon treatment of total DU145 with inhibitors targeting BMI-1 for 72hrs. B, IC50s of compounds C-209-211 assessed in DU145 cells through an ELISA assay. C, Effects of BMI-1 post-transcriptional inhibitors vs. the non-specific protein translation inhibitor cycloheximide (CHX), or the chemotherapeutics methotrexate (MTX) and doxorubicin on secondary (left) and tertiary (right) prostate spheroids formation. Treatments that were statistically significant were indicated as *p <0.05 and **p<0.01, compared to untreated.